Cargando…
Outcome Measures in Clinical Trials for Multiple Sclerosis
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess the true efficacy of interventions in clinical trials. In phase III trials in MS, the traditionally used prim...
Autores principales: | van Munster, Caspar E. P., Uitdehaag, Bernard M. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336539/ https://www.ncbi.nlm.nih.gov/pubmed/28185158 http://dx.doi.org/10.1007/s40263-017-0412-5 |
Ejemplares similares
-
Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
por: Uitdehaag, Bernard M. J.
Publicado: (2018) -
Minimal clinically important difference of improvement on the Arm
Function in Multiple Sclerosis Questionnaire (AMSQ)
por: van Munster, Caspar EP, et al.
Publicado: (2019) -
Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data
por: Goldman, Myla D., et al.
Publicado: (2019) -
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
por: van den Elskamp, I. J., et al.
Publicado: (2010) -
Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis
por: D’Souza, Marcus, et al.
Publicado: (2018)